Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. - Wikidata - awgldk - TriplyDB

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

http://www.wikidata.org/entity/Q34875287

about

Role of high-sensitivity C-reactive protein measurements in HIV patients Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda.HIV infection is associated with decreased thrombin generation Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy.Management of the metabolic effects of HIV and HIV drugs.Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.Adipose tissue and immune function: a review of evidence relevant to HIV infection.An association between adiposity and serum levels of macrophage inflammatory protein-1α and soluble CD14 in HIV-infected adults: results from a cross-sectional study.Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.C-Reactive Protein as an Independent Cardiovascular Risk Predictor in HIV+ Patients: A Focused Review of Published Studies.

P2860

Q28067891-40CEEDF6-430B-409D-995B-88E6876C5839 Q30248286-A757CB8F-D433-4F57-BD44-4ABE934E7323 Q31118978-AD013196-FE64-474A-8E79-7F9914AA7EA0 Q35107571-10C7A726-AAA4-4C98-8035-233731D586ED Q35845337-07D1B3FD-1B84-411B-950E-5200440BAABC Q35965242-0E1C60D8-3B45-4CCE-B9F6-70E47C29ADA0 Q35979650-DF942A63-2487-4183-9460-A562E3BC147C Q36021411-AFE4877F-5B7A-4C28-9C95-8AFE814EE1DD Q36116238-18D532DB-2D8F-4F3B-BBDA-4317260B3E0C Q36578046-20693C6C-89E4-4F9C-80C0-267BB3487737 Q37034835-1211EA00-F2B1-4B94-BD96-4D8EC43E40FC Q37187518-10D5A7C2-1874-49CB-B038-1386EED56E52 Q37581934-D2A43FE5-F130-477E-AE78-C0E28D39670B Q38603237-D4EC2579-93E2-44C7-A56C-F235019DC36B Q38858603-00FC932C-D89B-4033-9DD9-8CA8B95C6CC3 Q40504034-965C2491-5204-4E0B-8A15-1DB13D2BCD7D Q42373024-88505C08-4162-4D5B-8A4A-42450F6B39CA

P2860

Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.

http://www.wikidata.org/entity/Q34875287

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@ast

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@en

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@nl

type

label

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@ast

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@en

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@nl

prefLabel

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@ast

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@en

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@nl

P1433

Q34875287-A9A90406-6CCD-4936-925A-35BF8FCB2599

P1476

Q34875287-A149BCDD-F3EB-469F-ABFB-39B1DD8674AC

P2093

Q34875287-0D29BDF5-648B-4A2D-9683-7EBB40D7C377

Q34875287-17256167-9ACC-46D7-A76B-1DB176F2A8AC

Q34875287-19937ED8-1C0D-4199-98CA-BF9C76A33073

Q34875287-2D8ADBA0-3C03-492B-ACEC-3A20B6587156

Q34875287-40B3CF0E-2957-4A10-83F7-5A7E990502AF

Q34875287-70BD8A7B-9F59-4229-B202-A258BC5B67ED

Q34875287-75E6B2C3-2B44-40E6-BD64-698B3B4F7B9A

Q34875287-85DC515E-225F-4E46-9F6A-AF46282A8FC6

Q34875287-B956AEE1-6426-4227-BBB9-4F2A61D69392

Q34875287-FE6F1FD7-65ED-4CA9-9F45-C09D17347AA8

P2860

Q34875287-02C656B5-F502-4BC3-8927-B8FD39563D5A

Q34875287-1750FA7D-261E-4FB4-B24C-5FE7F1132063

Q34875287-17722B09-1364-41A3-A350-F80EA39D5E3C

Q34875287-1E49C8CD-E711-4BB2-A9C7-AF57C6950179

Q34875287-222A8085-829D-42DC-A98C-DA5E7D95931F

Q34875287-2B73CC78-2490-4891-B2C3-180BFBC1208B

Q34875287-2F56A290-2762-41C0-900F-8CFADC5837E4

Q34875287-36DBF059-955B-4A71-BEF1-AB57252EC583

Q34875287-391FE0A1-0EF9-4EA2-8E18-B4A6B83FBEFF

Q34875287-399C70EF-E8F5-467C-8664-129EEBFA4A70

P304

Q34875287-1827912E-4C75-44B1-9941-629BEA2F3AC0

P31

Q34875287-CF326EFA-831B-427A-B353-A33EC36A2AE8

P356

Q34875287-9C134045-4909-42A8-9068-2200D91785B5

P433

Q34875287-E82B7C17-4248-4B44-866E-49EE50A9F692

P478

Q34875287-12CE838C-0E8D-4A63-919B-301F0DF8903A

P577

Q34875287-C5379A33-4018-4522-87C3-60E7D4741E61

P698

Q34875287-11681D4D-8C17-4540-B0B4-497E3B4E1B6B

P921

Q34875287-511598C8-56DC-46CE-B32D-99BF21E6AD3B

P932

Q34875287-B51B19A1-0577-4D8C-976F-4D00B276C6B2

P356

P1433

AIDS Research and Human Retroviruses

P1476

Change in high-sensitivity c-r ...... s in HIV-infected individuals.

@en

P2093

AIDS Clinical Trials Group A5095 Study Team

http://www.w3.org/2001/XMLSchema#string

Barbara Bastow

http://www.w3.org/2001/XMLSchema#string

Cecilia M Shikuma

http://www.w3.org/2001/XMLSchema#string

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Heather J Ribaudo

http://www.w3.org/2001/XMLSchema#string

Karen T Tashima

http://www.w3.org/2001/XMLSchema#string

Marshall J Glesby

http://www.w3.org/2001/XMLSchema#string

Roy M Gulick

http://www.w3.org/2001/XMLSchema#string

William A Meyer

http://www.w3.org/2001/XMLSchema#string

Yu Zheng

http://www.w3.org/2001/XMLSchema#string

P2860

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

What does minor elevation of C-reactive protein signify?

Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

P304

461-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/AID.2010.0154

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20863238

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3083724

http://www.w3.org/2001/XMLSchema#string